Current NICE guidelines and technology appraisals include dapagliflozin (Forxiga) and empagliflozin (Jardiance) as recommended treatments for chronic heart failure with reduced ejection fraction. NICE NG106 refers to technology appraisal guidance on dapagliflozin and empagliflozin for treating chronic heart failure with reduced ejection fraction and advises following these in pharmacological management NICE NG106.
Regarding any ongoing or recent NICE reviews or consultations that could change these recommendations, the available context shows no mention of current or pending NICE reviews specific to heart failure treatment updates involving these drugs. The existing recommendations cite NICE technology appraisals already in place for dapagliflozin and empagliflozin NICE NG106.
Evidence supporting the current use includes results from large randomised controlled trials showing that empagliflozin significantly reduces the risk of cardiovascular death or hospitalisation for heart failure, and dapagliflozin shows superiority versus placebo in preventing hospitalisation for heart failure or cardiovascular death in patients with type 2 diabetes and cardiovascular risk factors or established disease SmPC Jardiance,SmPC Dapagliflozin,SmPC Dapagliflozin.
Consequently, although evidence supports their current use and inclusion in guidance, there is no information on ongoing NICE consultations or guideline reviews that may imminently change treatment recommendations for heart failure regarding Jardiance or Forxiga within the provided context.
Key References
- NICE CKS: Type 2 diabetes
- NICE NG106: Chronic heart failure in adults: diagnosis and management
- NICE NG28: Type 2 diabetes in adults: management
- SmPC: Qtern 5 mg/10 mg film-coated tablets
- SmPC: Jardiance 10 mg and 25 mg film-coated tablets
- SmPC: Dapagliflozin 5 mg film-coated tablets
- SmPC: Dapagliflozin 5 mg Film-coated Tablets
- NICE CKS: Kidney disease - chronic